CFTR and cystic fibrosis: The combination of tezacaftor and ivacaftor (TEZ/IVA, trade name Symdeko, Vertex Pharmaceuticals) was studied in CF individuals with two F508del mutations or one F508del and either one residual or one minimal function CFTR mutation.